natgillin/translations-raw huggingface dataset:
At last assessment (n = 10, 9 of whom had at least 72 months of treatment), median Z-score improvements from baseline were 1.93 for length/height and 2.43 for weight. 
Ob zadnjem ocenjevanju (N=10, od katerih se jih je 9 zdravilo vsaj 72 mesecev), je bilo mediano izboljšanje vrednosti Z od izhodišča 1,93 za dolžino/višino in 2,43 za telesno maso.
In the clinical trial setting, the majority of patients who experienced an injection site reaction had the first occurrence within the first 12 weeks of treatment with asfotase alfa, and some patients continued to experience injection site reactions until 1 or more years after initiating asfotase alfa dosing. 
V okviru kliničnega preskušanja se je večini bolnikov, ki so imeli reakcijo na mestu injiciranja, ta prvič pojavila v prvih 12 tednih zdravljenja z asfotazo alfa, nekateri bolniki pa so imeli reakcije na mestu injiciranja eno ali več let po začetku odmerjanja asfotaze alfa.
However, in pregnant rabbits administered intravenous doses of up to 50 mg/kg/day asfotase alfa, anti-drug antibodies were detected in up to 75% of animals which could affect the detection of reproductive toxicity. 
Vendar pa so pri brejih samicah kuncev, ki so jim dali intravenske odmerke asfotaz alfa do 50 mg/kg/dan, zaznali protitelesa proti zdravilu pri do 75 % živali, kar lahko vpliva na zaznavanje toksičnosti za reprodukcijo.
• The correct dose will be calculated by your doctor and consists of a total of 6 mg of asfotase alfa per kg of body weight every week, administered by injection under the skin (subcutaneous), (see the dosing chart below for detailed information on the volume to be injected, and the type of vials to be used, based on your weight). 
• Pravilni odmerek bo zdravnik izračunal in vsebuje skupaj 6 mg asfotaze alfa na kg telesne mase vsak teden, dan v obliki podkožne (subkutane) injekcije (glejte razpredelnico odmerjanja v nadaljevanju glede natančnih podatkov o volumnu, ki ga je treba vbrizgati, in vrsti vial, ki jo je treba uporabiti, na podlagi vaše telesne mase).
Strensiq is for subcutaneous use only. 
Zdravilo Strensiq je samo za subkutano uporabo.
Patients are advised to follow proper injection technique and to rotate injection sites (see section 4.2). 
Bolnikom se priporoča, da uporabljajo pravilno tehniko injiciranja in da menjujejo mesta injiciranja (glejte poglavje 4.2).
Tetracycline for bone-labelling was administered in two 3-day courses (separated by a 14-day interval) prior to acquisition of the bone biopsy. 
Tetraciklin za označevanje kosti je bil dan v dveh 3-dnevnih ciklih (med katerima je bil 14-dnevni interval) pred odvzemom biopsije kosti.
The need for supervision for subsequent administrations and need for emergency treatment for home care should be at the discretion of the treating physician. 
O potrebi po zdravniškem nadzoru ob naslednjih dajanjih zdravila in o zdravljenju v urgentnih primerih pri oskrbi na domu naj presodi lečeči zdravnik.
2 years 
6 mesecih.
Consider the risks and benefits of re-administering Strensiq to individual patients following a severe reaction, taking other factors into account that may contribute to the risk of a hypersensitivity reaction, such as concurrent infection and/ or use of antibiotics. 
Pred ponovnim dajanjem zdravila Strensiq posameznim bolnikom po resni reakciji pretehtajte razmerje med koristmi in tveganji zdravila, pri čemer upoštevajte tudi druge dejavnike, ki bi lahko prispevali k tveganju za preobčutljivostno reakcijo, kot sta sočasna okužba in/ali uporaba antibiotikov.
Step 1: Preparing the Strensiq dose 1. 
1. korak: Priprava odmerka zdravila Strensiq 1.
Patients received a median duration of treatment of 27.6 month (range from 1 day to 90 months). 
Bolniki so prejeli mediano trajanje zdravljenja 27,6 meseca (razpon od 1 dneva do 90 mesecev).
The syringes should be of small enough volume that the prescribed dose can be withdrawn from the vial with reasonable accuracy. 
Volumen injekcijske brizge mora biti dovolj majhen, da omogoča natančen odvzem predpisanega odmerka iz viale.
Name and address of the manufacturer of the biological active substance 
Ime in naslov proizvajalca biološke učinkovine Lonza Biologics
• Increase of parathyroid hormone concentration and low calcium levels have been reported in studies. 
• V študijah so poročali o zvišanju koncentracije obščitničnega hormona in nizkih ravneh kalcija.
For the time period of observation of historical controls: 1/16 patients displayed apparent catch-up heightgain, 12/16 patients did not display apparent catch-up height-gain and data were inconclusive in 3/16 patients. 
Za obdobje opazovanja zgodovinskih kontrolnih podatkov: pri 1 od 16 bolnikov se je pokazalo navidezno dohitevanje v pridobivanju višine, pri 12 od 16 bolnikov se ni pokazalo navidezno dohitevanje v pridobivanju višine in za 3 od 16 bolnikov podatki niso dovoljevali sklepanja.
• Instruction on how the injection site is chosen and how the injection is carried out and recorded 
• navodila o izbiri injekcijskega mesta in o izvedbi ter beleženju injiciranja,
Asfotase alfa is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Uporaba asfotaze alfa ni priporočljiva pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
69 patients completed the studies, and 11 discontinued. 
bolnikov dokončalo študiji, 11 pa ju je prekinilo.
How to inject Strensiq: 
Kako injicirati zdravilo Strensiq:
Holding the syringe like a pencil or a dart, insert the needle into the raised skin so it is at an angle of between 45º and 90º to the skin surface. 
Injekcijsko brizgo držite kot svinčnik ali puščico za pikado in iglo vstavite v privzdignjeno kožo tako, da je njen kot na površino kože med 45° in 90°.
In adult patients with pediatric-onset HPP, the pharmacokinetics of asfotase alfa at doses of 0.5, 2 and 3 mg/kg administered three times per week was consistent with those observed in pediatric patients with pediatric-onset HPP, and thus supported the approved dose of 6 mg/kg per week in treating adult patients with pediatric-onset HPP. 
Pri odraslih bolnikih s pediatričnim nastopom HPP se je farmakokinetika asfotaze alfa v odmerkih po 0,5, 2 in 3 mg/kg, danih trikrat na teden, ujemala s tisto, ki so jo ugotovili pri pediatričnih bolnikih s pediatričnim nastopom HPP, s čimer je podprla odobreni odmerek 6 mg/kg na teden za zdravljenje odraslih bolnikov s pediatričnim nastopom HPP.
Strensiq has no or negligible influence on the ability to drive and use machines. 
Zdravilo Strensiq nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
The treating physician should inform the testing lab that the patient is treated with medication affecting the ALP levels. 
Lečeči zdravnik mora obvestiti laboratorij, ki izvaja testiranje, da se bolnik zdravi z zdravilom, ki vpliva na ravni AF.
Based on its structure and pharmacokinetics, asfotase alfa is unlikely to affect Cytochrome P-450 related metabolism. 
Na podlagi svoje strukture in farmakokinetike ni verjetno, da bi asfotaza alfa vplivala na presnovo, povezano s citokromom P-450.
• This total dose can be given either as an injection of 1 mg/kg asfotase alfa 6 times per week or as 2 mg/kg asfotase alfa 3 times per week depending on the recommendation of your doctor. 
• Ta skupni odmerek se da kot injekcija 1 mg/kg asfotaze alfa 6-krat na teden ali kot 2 mg/kg asfotaze alfa 3-krat na teden, odvisno od priporočila zdravnika.
Do not rub the injection site after injection. 
Mesta injiciranja po injiciranju ne drgnite.
Table 1: Adverse Reactions Reported in clinical trials in hypophosphatasia patients (age 1 day to 66 years, treatment duration range from 1 day to 391 weeks [7.5 years]) 
Preglednica 1: Neželeni učinki, o katerih so poročali v kliničnih preskušanjih z bolniki s hipofosfatazijo (starimi 1 dan do 66 let), razpon trajanja zdravljenja od 1 dneva do 391 tednov [7,5
Only clear and colourless to slightly yellow aqueous solution without visible signs of deterioration should be used. 
Uporabljate lahko le bistro in brezbarvno do rahlo rumenkasto vodno raztopino brez vidnih znakov kvarjenja.
Craniosynostosis as a manifestation of hypophosphatasia is documented in published literature and occurred in 61.3% of patients between birth and 5 years of age in a natural history study of untreated infantile-onset hypophosphatasia patients. 
Kraniosinostoza kot manifestacija hipofosfatazije je dokumentirana v objavljeni literaturi in se je pojavila pri 61,3 % bolnikov med rojstvom in 5. letom starosti v študiji naravnega poteka bolezni pri bolnikih z nezdravljeno hipofosfatazijo z zgodnjim nastopom.
For those patients who received asfotase alfa: 11/13 patients displayed persistent apparent catch-up heightgain as shown by movement over time to a higher percentile on CDC growth charts. 
Za bolnike, ki so prejemali asfotazo alfa: 11 od 13 bolnikov je kazalo vztrajno navidezno dohitevanje pridobivanja višine, kot prikazuje gibanje v času, do višjih percentil na tablicah rasti CDC.
Push the plunger in completely to inject the air into the vial. 
Potisnite bat noter do konca, da boste vbrizgali zrak v vialo.
• Instructions on the correct dose to be administered 
• navodila o pravilnem odmerku, ki naj ga prejema bolnik,
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
Znotraj vsake skupine pogostnosti so neželeni učinki na zdravilo navedeni po padajoči resnosti.
Histological analysis of biopsies used Osteomeasure software (Osteometrics, USA). 
Za histološke analize biopsij so uporabili programsko opremo Osteomeasure (Osteometrics, ZDA).
Twenty five percent (15 out of 60) of the overall patient population was adult (>18 years) at baseline. 
Petindvajset odstotkov (15 od 60) celokupne populacije bolnikov je bilo ob izhodišču odraslih
Each vial is intended for single use only and should only be punctured once. 
Ena viala je namenjena enkratni uporabi in jo je dovoljeno le enkrat prebosti.
Please discuss with you doctor or nurse the best sites for you. 
Pogovorite se z zdravnikom ali medicinsko sestro o tem, kateri predeli so za vas najprimernejši.
The educational programme is aimed to provide instruction to patients and carers for proper administration techniques to address the risks of medication errors and injection site and injection associated reactions, including hypersensitivity. 
Cilj izobraževalnega programa je zagotoviti navodila glede pravilnih tehnik uporabe zdravila bolnikom in njihovim skrbnikom, ki bodo odgovorila tudi na vprašanja o tveganju napak pri uporabi zdravila in o reakcijah na mestu injiciranja ter o reakcijah, povezanih z injiciranjem, vključno s preobčutljivostjo.
Nephrocalcinosis occurred in 51.6% of patients between birth and 5 years of age in a natural history study of untreated infantile-onset hypophosphatasia patients. 
Nefrokalcinoza se je pojavila pri 51,6 % bolnikov med rojstvom in starostjo 5 let v študiji naravnega poteka bolezni pri bolnikih z nezdravljeno hipofosfatazijo z infantilnim nastopom.
2 ml or 3 ml vial (Type I glass) with a stopper (butyl rubber) and a seal (aluminium) with a flip-off cap (polypropylene). 
2-mililitrska ali 3-mililitrska viala (steklo tipa I) z zamaškom (butilna guma) in tesnilom (aluminij) z dvižno zaporko (polipropilen).
One patient withdrew from the trial due to injection site hypersensitivity. 
En bolnik se je umaknil iz kliničnega preskušanja zaradi preobčutljivosti na mestu injiciranja.
If you use more Strensiq than you should 
Če ste uporabili večji odmerek zdravila Strensiq, kot bi smeli
Serum parathyroid hormone concentration may increase in hypophosphatasia patients administered asfotase alfa, most notably during the first 12 weeks of treatment. 
Koncentracije obščitničnega hormona se lahko pri bolnikih s hipofosfatazijo, ki dobijo asfotazo alfa, povečajo, najbolj opazno v prvih 12 tednih zdravljenja.
Pharmacokinetics of asfotase alfa were evaluated in a 1-month, multicenter, open-label, dose-escalating, study in adults with hypophosphatasia. 
Farmakokinetiko asfotaze alfa so ocenili v 1-mesečni, multicentrični, odprti študiji z večanjem odmerka pri odraslih s hipofosfatazijo.
Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease (see section 5.1). 
Zdravilo Strensiq je indicirano za dolgotrajno encimsko nadomestno zdravljenje pri bolnikih s pediatričnim nastopom hipofosfatazije za zdravljenje manifestacij te bolezni na kosteh (glejte poglavje 5.1).
Among those 97 patients, 55 (56.7%) also showed the presence of neutralizing antibodies at some time point post-baseline. 
97 bolniki se je pri 55 (56,7 %) pokazala v neki časovni točki po izhodišču tudi prisotnost nevtralizirajočih protiteles.
Following repeated subcutaneous administration to pregnant mice in the therapeutic dose range (>0.5 mg/kg), asfotase alfa levels were quantifiable in fetuses at all doses tested, suggesting cross-placental transport of asfotase alfa. 
Po ponavljajočem subkutanem dajanju zdravila brejim mišim v terapevtskem območju odmerkov (> 0,5 mg/kg) je bilo mogoče ravni asfotaze alfa pri zarodkih določiti za vse testirane odmerke, kar nakazuje na prehajanje asfotaze alfa skozi posteljico.
Severe or potentially life-threatening hypersensitivity is a contraindication to re-challenge, if hypersensitivity is not controllable (see section 4.3). 
Resna ali življenje ogrožajoča preobčutljivost je kontraindikacija za ponovno uporabo zdravila, če preobčutljivosti ni mogoče obvladati (glejte poglavje 4.3).
Adverse reactions with asfotase alfa are listed by system organ class and preferred term using MedDRA frequency convention very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). 
Neželeni učinki z asfotazo alfa so našteti glede na organski sistem in posamezen izraz, upoštevajoč MedDRA konvencijo za pogostnost: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki
As in adults, the recommended dosage of Strensiq in children and adolescents is 6 mg of asfotase alfa per kg weekly. 
Kot pri odraslih je priporočeni odmerek zdravila Strensiq pri otrocih in mladostnikih 6 mg asfotaze alfa na kg na teden.
The model identified body weight to affect asfotase alfa clearance and volume of distribution parameters. 
Z modelom je bilo ugotovljeno, da telesna masa vpliva na parametre očistka asfotaze alfa in volumna porazdelitve.
Severe or life-threatening hypersensitivity to the active substance or to any of the excipients if hypersensitivity is not controllable (see section 4.4). 
Huda ali življenje ogrožajoča preobčutljivost na učinkovino ali katero koli pomožno snov, če preobčutljivosti ni mogoče obvladati (glejte poglavje 4.4.
Asfotase alfa contains a catalytic domain of tissue non-specific alkaline phosphatase. 
Asfotaza alfa vsebuje katalitično domeno tkivno nespecifične alkalne fosfataze.
Clear, colourless to slightly yellow, aqueous solution; pH 7.4. 
Bistra, brezbarvna do rahlo rumenkasta vodna raztopina s pH 7,4.
• The development of blood proteins against Strensiq, also called anti-drug antibodies, may occur during the treatment. 
• Med zdravljenjem se lahko razvijejo krvne beljakovine proti zdravilu Strensiq, ki se imenujejo tudi protitelesa proti zdravilu.
• In studies, some eye-related side-effects have been reported both in patients using Strensiq and those who were not, probably associated with hypophosphatasia. 
• V študijah so pri bolnikih, ki so uporabljali zdravilo Strensiq, in pri tistih, ki ga niso, poročali o nekaterih neželenih učinkih, povezanih z očesom, ki so verjetno povezani s hipofosfatazijo.
Do not use this medicine after the expiry date which is stated on the carton and the vial label after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki viale poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
There was no evidence of ectopic calcification observed in any other tissues examined. 
Na drugih pregledanih tkivih niso opazili dokazov ektopične kalcifikacije.
• Hypersensitivity reactions have been observed in patients treated with Strensiq, including a description of sign and symptoms 
• pri bolnikih, zdravljenih z zdravilom Strensiq, so opazili preobčutljivostne reakcije, vključno z opisom znakov in simptomov,
Administration of asfotase alfa will interfere with routine measurement of serum alkaline phosphatase by hospital laboratories resulting in serum alkaline phosphatase activity measurements of several thousand units per litre. 
Dajanje asfotaze alfa bo vplivalo na rutinske meritve alkalne fosfataze v serumu, ki jih opravljajo bolnišnični laboratoriji, in povzročijo meritve aktivnosti alkalne fosfataze več tisoč enot na liter.
Trans-iliac crest bone biopsies were obtained by standard procedure. 
Biopsije transčrevničnega grebena so odvzeli s standardnim postopkom.
There are insufficient data to establish a causal relationship between exposure to Strensiq and ectopic calcification. 
Ni dovolj podatkov za dokaz vzročne povezave med izpostavljenostjo zdravilu Strensiq in ektopično kalcifikacijo.
Hypophosphatasia is a rare, severe, and potentially fatal, genetic disorder caused by loss-of-function mutation(s) in the gene encoding tissue non-specific alkaline phosphatase. 
Hipofosfatazija je redka, huda in potencialno smrtna prirojena bolezen, ki jo povzroči mutacija/-e gena z izgubo funkcije, ki kodira tkivno nespecifično alkalno fosfatazo.
Based on the results of population pharmacokinetic analysis it was concluded that asfotase alfa exhibits linear pharmacokinetic up to subcutaneous doses of 28 mg/kg/week. 
Na podlagi rezultatov populacijske farmakokinetične analize so sklepali, da je farmakokinetika asfotaze alfa linearna do subkutanih odmerkov 28 mg/kg/teden.
• If you are treated with Strensiq, you may experience a reaction at the injection site (pain, nodule, rash, discoloration) during the injection of the medicine or during the hours following the injection. 
• Če se zdravite z zdravilom Strensiq, boste morda imeli reakcijo na mestu injiciranja (bolečino, zatrdlino, izpuščaj, obarvanje) med injiciranjem zdravila ali v urah, ki sledijo injiciranju.
A total of 24/69 (35%) patients displayed apparent catch-up height-gain and 32/69 (46%) patients displayed apparent catch-up weight-gain, as shown by movement over time to a higher percentile on CDC growth charts. 
Skupaj 24 od 69 (35 %) bolnikov je pokazalo navidezno dohitevanje pridobivanja telesne višine, 32 od 69 (46 %) bolnikov pa je pokazalo navidezno dohitevanje pridobivanja telesne mase, kot kaže gibanje v času proti naslednjemu percentilu na rastnih shemah CDC.
Localized lipodystrophy, including lipoatrophy and lipohypertrophy, has been reported at injection sites after several months in patients treated with STRENSIQ in clinical trials (see section 4.8). 
O lokalizirani lipodistrofiji, vključno z lipoatrofijo in lipohipertrofijo, na mestu injiciranja so pri bolnikih, zdravljenih z zdravilom STRENSIQ v kliničnih preskušanjih, poročali po več mesecih (glejte poglavje 4.8).
Elderly There is no evidence for special considerations when Strensiq is administered to elderly patients. 
Ni dokazov o tem, da bi bila pri dajanju zdravila Strensiq starejšim bolnikom potrebna posebna previdnost.
(SD) AUC over the dosing interval (AUCτ) was 66034 (19241) and 40444 (N=1) U*h/L following the first and the third dose, respectively. 
med odmernim intervalom (AUCτ) 66.034 (19.241) po prvem oz. 40.444 (N = 1) e*h/l po tretjem odmerku.
Any unused solution in the vial should be discarded. 
Morebitno neuporabljeno raztopino v viali je treba zavreči.
Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). 
Ni dovolj študij na živalih o vplivu zdravila na sposobnost razmnoževanja (glejte poglavje 5.3).
Read section 4 carefully to know what side effects can occur before using this medicine 
Pred uporabo tega zdravila natančno preberite poglavje 4, da boste vedeli, kateri neželeni učinki se lahko pojavijo.
If it is the case, multiple injections should be done at different sites. 
Če presega, dajte več injekcij na različnih mestih.
A few case reports of anaphylactoid/hypersensitivity reaction have been received in the clinical trial setting. 
Prejeli so nekaj poročil o primerih anafilaktoidnih/preobčutljivostnih reakcij v okviru kliničnih preskušanj.
• Information on reporting side effect 
• informacije o poročanju neželenih učinkov.
Not all pack sizes may be marketed in your country. 
Na trgu morda ni vseh navedenih pakiranj.
Subcutaneous use. 
subkutana uporaba
Pharmacotherapeutic group: Other alimentary tract and metabolism products, enzymes, ATC code: A16AB13 
Farmakoterapevtska skupina: druga zdravila za bolezni prebavil in presnove, encimi, oznaka ATC:
Serum Parathyroid Hormone and Calcium 
Ravni obščitničnega hormona in kalcija v serumu
This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. the product is essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni "brez natrija".
• If you are injecting this medicine yourself, you will be shown how to prepare and inject the medicine by your doctor, pharmacist or nurse. 
• Če si zdravilo injicirate sami, vam bo zdravnik, farmacevt ali medicinska sestra pokazal, kako si zdravilo pripravite in injicirate.
After the 3 mg/kg for 1.08 hours intravenous infusion, the median time (Tmax) ranged between 1.25 to 1.50 hours, and the mean (SD) Cmax ranged between 42694 (8443) and 46890 (6635) U/L over the studied cohorts. 
Po intravenski infuziji 3 mg/kg v 1,08-ure je bil razpon medianega časa (Tmax) od 1,25 do 1,50 ure, srednja vrednost (SD) Cmax pa je bila v proučevanih kohortah v območju med 42.694 (8.443) in 46.890 (6.635) e/l.
If you suspect that you have been accidently administered a higher dose of Strensiq than prescribed, please contact your doctor for advice. 
Če sumite, da ste prejeli večji odmerek zdravila Strensiq, kot vam je bil predpisan, se za nasvet obrnite na zdravnika.
Asfotase alfa, a human recombinant tissue-nonspecific alkaline phosphatase-Fc-deca-aspartate fusion protein with enzymatic activity, promotes mineralisation of the skeleton in patients with hypophosphatasia. 
Asfotaza alfa, humana rekombinantna tkivno nespecifična alkalna fosfataza-Fc-deka-aspartatni fuzijski protein z encimsko aktivnostjo spodbuja mineralizacijo skeleta pri bolnikih s hipofosfatazijo.
MARKETING AUTHORISATION NUMBER(S) EU/1/15/1015/003 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/15/1015/003
Remove the needle from the vial and place back the protective cap over the needle. 
Odstranite iglo iz viale in spet namestite zaščitni pokrovček na iglo.
Trained radiologists evaluated pre- and post-baseline x-rays of wrists and knees of patients for the following signs: apparent physeal widening, metaphyseal flaring, irregularity of provisional zone of calcification, metaphyseal radiolucencies, metadiaphyseal sclerosis, osteopenia, ‘popcorn' calcification in metadiaphysis, demineralization of distal metaphysis, transverse subphyseal band of lucency and tongues of radiolucency. 
Usposobljeni radiologi so ocenjevali rentgenske posnetke zapestij in kolen bolnikov pred izhodiščem in po izhodišču in ugotavljali naslednje znake: navidezna fizna razširitev, metafizni izbruh, nepravilnosti začasne cone kalcifikacije, metafizne radiotransparence, metadiafizna skleroza, osteopenija, "popcorn" kalcifikacije v metadiafizi, demineralizacija distalne metafize, transverzen subfizni trak transparence in pasovi radiotransparence.
Ophthalmic (conjunctival and corneal) calcification and nephrocalcinosis as manifestations of hypophosphatasia are documented in published literature. 
Očesna (veznična in roženična) kalcifikacija in nefrokalcinoza kot manifestaciji hipofosfatazije sta dokumentirani v objavljenih virih.
Step 4: Injecting Strensiq 
4. korak: Injiciranje zdravila Strensiq
Table 1 gives the adverse reactions observed from clinical trials. 
V preglednici 1 so navedeni neželeni učinki, ki so jih opazili v kliničnih preskušanjih.